Katya Tsaioun, Ph.D.
President, Apredica, Inc.
Dr. Tsaioun is founder and President of Apredica, which specializes in rapid preclinical in vitro assessment of the ADME Tox properties of small-molecule and peptide therapeutics. Prior to founding Apredica, Dr. Tsaioun worked as a Group Leader at Surface Logix, where she built a team and developed a complete in vitro ADME program, which was a central part of the company’s technology platform for optimizing and advancing drug leads. Prior to Surface Logix, Dr. Tsaioun worked at Mitotix (subsequently merged into GPC Biotech), where she pioneered cell-based assay development in the area of angiogenesis (oncology) and infectious disease. She earned her Ph.D. in Biochemistry from Tufts University and got a post-doctoral training in Neurochemistry at the Harvard Medical School.
Dr. Tsaioun is active in many local and international professional and business societies and is a co-founder and a member of the board of WEALTH (Women Executives Advancing Life Sciences, Technology and Health). She is also a co-founder and member of the management team of Pharma Launcher, a consortium of pharmaceutical CROs.